事件描述2025 年3 月26 日，信达生物发布2024 年业绩报告：2024 年首次实现Non-IFRS 利润转正，总收入94.2 亿元（同比+51.8%），产品收入82.3 亿元人民币（同比+43.6%），净利润3.3 亿元，EBITDA 4.1 亿元，毛利率84.9%（同比+2.1%），销售和行政开支比率50.9%（同比-7.1%），在手现金102.2 亿元，研发投入25.0 亿元。事件评论...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.